December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Working with corporate venture funds?

Working with corporate venture funds?

What are the benefits or constraints to go to a corporate venture tool? Is it better to go with a pharma player that wants to be a limited partner in existing funds rather than corporate ventures? AS both have fundamentally different missions, what are the validating and limitation effects of working with a corporate VC? How to balance these two effects?

Joachim Vogt

Director, Search and Evaluation International
AbbVie

Pierre D’Epenoux

CEO
Imcheck Therapeutics

Isaac Haq

Analyst
ArchiMed Group

Lionel Carnot

Partner
EARLYBIRD

Cheryl Zimberlin

Principal
M VENTURES
Scroll to Top